CSIMarket
 
Clearside Biomedical Inc   (CLSD)
Other Ticker:  
 
 
Price: $1.5600 $-0.15 -8.772%
Day's High: $1.78 Week Perf: -4.88 %
Day's Low: $ 1.49 30 Day Perf: 27.87 %
Volume (M): 858 52 Wk High: $ 2.12
Volume (M$): $ 1,339 52 Wk Avg: $1.11
Open: $1.78 52 Wk Low: $0.65



 Market Capitalization (Millions $) 97
 Shares Outstanding (Millions) 62
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) -25
 Capital Exp. (TTM) (Millions $) 2

Clearside Biomedical Inc
Clearside Biomedical Inc is a biopharmaceutical company focused on developing targeted therapies to treat diseases of the eye. The company utilizes its proprietary technology, known as suprachoroidal space (SCS) injection, to deliver drugs to the back of the eye, specifically targeting the retina and choroid. Clearside's SCS injection technique offers a non-invasive and potentially more effective method of drug delivery compared to traditional methods.

The company's flagship product, XIPERE (formerly known as CLS-TA), is an investigational treatment for macular edema associated with uveitis. XIPERE is designed to be administered via SCS injection, allowing for targeted drug delivery to the affected area of the eye. Clearside also has several other product candidates in its pipeline, including treatments for diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion.

Clearside Biomedical Inc is committed to improving patient outcomes in ophthalmology and is actively conducting clinical trials to assess the safety and efficacy of its therapies. The company's innovative approach to drug delivery and focus on ophthalmic conditions set it apart in the biopharmaceutical industry.


   Company Address: 900 North Point Parkway Alpharetta 30005 GA
   Company Phone Number: 270-3631   Stock Exchange / Ticker: NASDAQ CLSD
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Changes

Clearside Biomedical Appoints Chief Medical Officer with Extensive Retinal Disease Research Background Amidst Financial Struggles

Published Mon, Mar 18 2024 11:05 AM UTC



Clearside Biomedical Inc, a biopharmaceutical company specializing in retinal disease research and clinical development, recently announced the appointment of Victor Chong, M.D., MBA as their Chief Medical Officer. Dr. Chong brings with him a wealth of experience and a proven track record in advancing programs through clinical development, making him a valuable add...

Clearside Biomedical Inc

Clearside Biomedical Inc. Struggles to Attain Profitability Despite Exponential Revenue Growth in Q3 of 2023

Clearside Biomedical Inc's recent announcement of very solid revenue growth of 222.932% year on year may seem impressive at first glance. However, a closer examination reveals significant concerns that raise doubts about the company's future prospects.
Firstly, despite the reported revenue surge, Clearside Biomedical Inc's deficit has extended to $-0.15. This is a deeply concerning figure and raises questions about the company's ability to generate sustainable profits. A growing deficit indicates that the company's expenses are exceeding its revenue, a red flag for any investor.

Clearside Biomedical Inc

Clearside Biomedical Inc's Impressive Revenue Growth Masks Concerns Over Diminishing Returns and Net Deficit



Clearside Biomedical Inc (NASDAQ: CLSD) has recently announced an impressive revenue growth rate of 165.104% year-on-year, reaching $1.02 million for the three-month period ending on June 30, 2023. While this growth is undoubtedly positive news for the company, there are some concerning factors surrounding diminishing returns. This article will delve into Clearside Biomedical's latest financial performance, its net deficit, and the current state of its stock.
1. Revenue Growth:
Clearside Biomedical Inc's revenue surge of 165.104% year-on-year is undoubtedly admirable. It indicates that the company's products or services have gained traction in the market, attracting more customers and generating higher sales. However, it's essential to analyze this success in conjunction with the company's diminishing returns.

Clearside Biomedical Inc

Clearside Biomedical Inc Faces Alarming Losses with Revenue Plummeting to $0.00 Million

In the latest blow to the pharmaceutical industry, Clearside Biomedical Inc has posted alarming losses in its most recent fiscal period. According to the company's disclosure, its revenue has taken a significant plunge, dropping to $0.00 million overall. Furthermore, there was an increased net deficit per share to $-0.15, which is a worrying trend compared to the similar reporting season a year ago. This marks a decline from the previous period, where the company posted $-0.16 per share and $0.33 million in revenue.
The numbers are even bleaker when we look at the period between January to March 31, 2023. That time-frame saw a massive net loss of $-9.280 million, which is a troubling increase from $-7.644 million over the same period the previous year. It's apparent that Clearside Biomedical Inc is facing severe financial difficulties.






 

Clearside Biomedical Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com